Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

CLL incidence and prevalence have decreased globally, but regional disparities exist, with high-SDI regions seeing declines and low-SDI regions experiencing stable or increasing rates. Mortality ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Imbruvica is a prescription drug used in adults with chronic lymphocytic leukemia (CLL), a type of cancer that starts in the bone marrow. The drug is available in three oral forms: a capsule, tablet, ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...